{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2025"],"submitter":["Lin KH"],"pubmed_abstract":["Patients with chronic lymphocytic leukemia (CLL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) eventually discontinue treatment, but data on outcomes post-BTKi treatment discontinuation are limited. In this single-institution, retrospective chart review of 104 adult patients with CLL treated with a covalent BTKi between July 2011 and April 2019 and who subsequently discontinued for any reason, the majority of patients (59.9%) received the index BTKi in their first (27.5%) or second (32.4%) line of therapy. Median progression-free survival (PFS) from index BTKi initiation was 3.2 years, and median overall survival (OS) was 8.9 years. There was a notable correlation between PFS and OS (<i>r</i> = 0.79). Following the discontinuation of their last BTKi treatment, over half "],"journal":["Advances in hematology"],"pagination":["7492594"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12665162"],"repository":["biostudies-literature"],"pubmed_title":["Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center."],"pmcid":["PMC12665162"],"pubmed_authors":["Yang X","Gandra SR","Zanardo E","Farooqui MZH","Duh MS","Lin KH","Huynh L","Davids MS","Liborski D","De Nigris E","McDonough MM","Brown JR"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.","description":"Patients with chronic lymphocytic leukemia (CLL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) eventually discontinue treatment, but data on outcomes post-BTKi treatment discontinuation are limited. In this single-institution, retrospective chart review of 104 adult patients with CLL treated with a covalent BTKi between July 2011 and April 2019 and who subsequently discontinued for any reason, the majority of patients (59.9%) received the index BTKi in their first (27.5%) or second (32.4%) line of therapy. Median progression-free survival (PFS) from index BTKi initiation was 3.2 years, and median overall survival (OS) was 8.9 years. There was a notable correlation between PFS and OS (<i>r</i> = 0.79). Following the discontinuation of their last BTKi treatment, over half ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T07:19:00.498Z","creation":"2026-06-06T03:06:50.029Z"},"accession":"S-EPMC12665162","cross_references":{"pubmed":["41328215"],"doi":["10.1155/ah/7492594"]}}